
EMS
Brazilian pharmaceutical manufacturer with a portfolio spanning generics, prescription, and OTC medicines.

Brazilian pharmaceutical manufacturer with a portfolio spanning generics, prescription, and OTC medicines.
ems.com.brCrawled Oct 15, 2026
miRecule announces a strategic research collaboration with Rio Biofarma Brasil Ltda. (RBBL), an EMS S.A. company, to co-develop peptide-mediated delivery technologies for RNA therapeutics targeting extra-hepatic tissues. The collaboration combines miRecule’s NAVIgGator platform with RBBL’s peptide discovery and manufacturing; RBBL also makes an equity investment, manufactures resulting products at its Brazilian facility, and receives technology co-ownership, with up to three oligo payload targets.
Jul 2026miRecule, Inc. (company press release; syndicated on BusinessWire)News article
EMS and BD launch EMS's semaglutide therapy in Brazil using BD's Vystra injection-pen platform for patients with obesity and type 2 diabetes. EMS Vice President Gabriel Sanchez says the launch is an important step toward expanding access to advanced metabolic therapies in the country.
Jul 2026BD newsroom / PRNewswireNews article
EMS acquires Fresenius Kabi Brasil’s injectable-medicines portfolio and Anápolis manufacturing plant, expanding its hospital segment. The transfer runs through Newcom Farmacêutica Ltda. under Anvisa RDC 903/2024, with no changes to the products’ technical-sanitary characteristics, formulations, approved indications, validated production sites, factory prices or maximum consumer prices.
Jun 2026CDPI PharmaNews article
EMS announces Anvisa approval for OZIVY, a semaglutide-based GLP-1 pen indicated to treat type 2 diabetes. The company produces the pen at its peptide plant in Hortolândia, São Paulo, which has capacity for up to 40 million pens annually and uses a proprietary platform backed by more than R$1.2 billion in investment. Anvisa classifies OZIVY as a new medicine, not a generic, similar medicine or biosimilar; it follows EMS launches OLIRE and LIRUX.
May 2026Anvisa (gov.br news)News article